Zeposia is an oral sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing MS.
-
NHE
- Volunteer Moderator
- Posts: 5593
- Joined: Sat Nov 20, 2004 3:00 pm
-
Contact:
Post
by NHE » Sun May 03, 2020 3:29 am
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Mult Scler. 2019 Aug;25(9):1255-1262.
- BACKGROUND: Ozanimod, an oral immunomodulator, selectively targets sphingosine 1-phosphate receptors 1 and 5.
OBJECTIVE: Evaluate efficacy, safety, and tolerability of ozanimod in relapsing multiple sclerosis.
METHODS: In the RADIANCE Part A phase II study (NCT01628393), participants with relapsing multiple sclerosis were randomized (1:1:1) to once-daily ozanimod hydrochloride (0.5 or 1 mg) or placebo. After 24 weeks, participants could enter a 2-year, dose-blinded extension. Ozanimod-treated participants continued their assigned dose; placebo participants were re-randomized (1:1) to ozanimod hydrochloride 0.5 or 1 mg (equivalent to ozanimod 0.46 and 0.92 mg).
RESULTS: A total of 223 (89.6%) of the 249 participants completed the blinded extension. At 2 years of the extension, the percentage of participants who were gadolinium-enhancing lesion-free ranged from 86.5% to 94.6%. Unadjusted annualized relapse rate during the blinded extension (week 24-end of treatment) was 0.32 for ozanimod hydrochloride 0.5 mg → ozanimod hydrochloride 0.5 mg, 0.18 for ozanimod hydrochloride 1 mg → ozanimod hydrochloride 1 mg, 0.30 for placebo → ozanimod hydrochloride 0.5 mg, and 0.18 for placebo → ozanimod hydrochloride 1 mg. No second-degree or higher atrioventricular block or serious opportunistic infection was reported.
CONCLUSION: Ozanimod demonstrated sustained efficacy in participants continuing treatment up to 2 years and reached similar efficacy in participants who switched from placebo; no unexpected safety signals emerged.
Free full text.
-
-
- 0 Replies
- 198 Views
-
Last post by NHE
Sat Apr 25, 2020 2:33 am
-
-
Cardiac Safety of Ozanimod
Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.
Clin Pharmacol Drug Dev. 2018...
- 0 Replies
- 594 Views
-
Last post by NHE
Sun May 03, 2020 4:07 am
-
-
Ozanimod RADIANCE Phase III Trial
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3...
- 0 Replies
- 224 Views
-
Last post by NHE
Sat Apr 25, 2020 4:42 am
-
-
Ozanimod SUNBEAM Phase III Trial
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month,...
- 0 Replies
- 210 Views
-
Last post by NHE
Sat Apr 25, 2020 4:51 am
-
-
Ozanimod approved
Ozanimod was approved by the FDA in March 2020 with the trade name Zeposia. More information in the links below.
- 0 Replies
- 301 Views
-
Last post by frodo
Mon Apr 13, 2020 12:20 am
-
-
Ozanimod expected in March
Probably Ozanimod will be approved in March.
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) both agreed to...
- 0 Replies
- 360 Views
-
Last post by frodo
Tue Jan 14, 2020 1:23 am
-
-
Life Extension Foundation
Here's an interesting article about William Faloon, the founder of the supplement company Life Extension.
- 0 Replies
- 6312 Views
-
Last post by NHE
Mon Oct 07, 2019 10:34 am
-
-
- 0 Replies
- 624 Views
-
Last post by frodo
Fri Jan 17, 2020 3:08 am
-
-
- 0 Replies
- 823 Views
-
Last post by frodo
Fri Jan 17, 2020 2:54 am